Gilead Stock Rises as HIV Prevention Injection Meets Study Goals

Gilead Sciences, Inc. (GILD) announced upbeat results from an interim analysis of a second late-stage study evaluating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV.Results showed that lenacapavir, administered twice yearly, not only reduced HIV infections by 96% but also demonstrated superiority to Gilead’s daily HIV pill Truvada.The strong results validated lenacapavir’s potential to prevent HIV. Investors were impressed and GILD stock was ...